Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Global Osteoporosis Market 2016 Share, Trend, Segmentation and Forecast to 2019

Wednesday, November 9, 2016 23:58
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Osteoporosis is a silent disease until it is complicated by fractures that occur following minimal trauma or, in some cases, with no trauma. Globally Osteoporosis is expected to be more than US$ 40 Billion market by 2019. China and India together have close to 80% of osteoporosis patients worldwide. Whereas this in case of hip fracture cases both the countries China and India have more than 60% patients. But when we study Osteoporosis in market terms then United States controls the highest market share followed by China and Japan. Amgen and Eli Lilly are two dominant players in Osteoporosis drugs market.

Request a sample report @ https://www.wiseguyreports.com/sample-request/529617-global-osteoporosis-market-patients-companies-forecast

This is the 2nd edition report on Osteoporosis by Research. Report titled “Global Osteoporosis Market, Patients, Companies & Forecast” provides a comprehensive analysis of the current state of this market and likely future evolution over the next 5 years. This 124 page report with 89 Figures and 8 Tables studies the Worldwide Osteoporosis market from 6 view points:

1) Osteoporosis Patients & Forecast 
2) Hip fracture Patients & Forecast 
3) Osteoporosis Market & Forecast 
4) Country Wise Osteoporosis level of Awareness, Guidelines & Policy 
5) Country Wise Reimbursement of Medication 
6) Company Wise Osteoporosis Drugs Sales & Forecast

All the 10 Countries studied in the report are as follows

1) India 
2) China 
3) Japan 
4) Korea 
5) Brazil 
6) Russia 
7) United Kingdom 
8) France 
9) Germany 
10) United States

Worldwide Osteoporosis – Company Wise Drugs Sales Analysis (2010 – 2019)

1) Merck 
2) Sanofi 
3) Novartis 
4) Eli Lilly 
5) Amgen

Data Sources

This report is built using data and information sourced from proprietary databases, primary and secondary research and in–house analysis by Research team of industry experts.

Primary sources include industry surveys and telephonic interviews with industry experts.

Secondary sources information and data has been collected from various printable and non–printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 500 paid databases.

Complete report details @ https://www.wiseguyreports.com/reports/529617-global-osteoporosis-market-patients-companies-forecast      

Key points in table of content

1. Executive Summary

2. Worldwide Osteoporosis Patients Population Analysis 
    2.1 Worldwide Osteoporosis Patients Population (2010 – 2019) 
    2.2 Worldwide Hip Fracture Patients Population (2010 – 2019)

3. Worldwide Osteoporosis Market (2010 – 2019)

4. Worldwide Osteoporosis Share Analysis 
    4.1 Worldwide Osteoporosis Patients Population Share (2010 – 2019) 
    4.2 Worldwide Hip Fracture Patients Population Share (2010 – 2019) 
    4.3 Worldwide Osteoporosis Market Share (2010 – 2019) 
    4.4 Worldwide Osteoporosis Drugs Company Market Share (2010 – 2019)

5. India 
    5.1 India Osteoporosis Patients Population (2010 – 2019) 
    5.2 India Hip Fracture Patients Population (2010 – 2019) 
    5.3 India Osteoporosis Market (2010 – 2019) 
    5.4 Level of Awareness 
    5.5 Fracture Registries 
    5.6 Government Policies 
    5.7 Guidelines 
    5.8 Reimbursement of Medication

6. China 
    6.1 China Osteoporosis Patients Population (2010 – 2019) 
    6.2 China Hip Fracture Patients Population (2010 – 2019) 
    6.3 China Osteoporosis Market (2010 – 2019) 
    6.4 Level of Awareness 
    6.5 Fracture Registries 
    6.6 Government Policies 
    6.7 Guidelines 
    6.8 Reimbursement of Medication

7. Japan 
    7.1 Japan Osteoporosis Patients Population (2010 – 2019) 
    7.2 Japan Hip Fracture Patients Population (2010 – 2019) 
    7.3 Japan Osteoporosis Market (2010 – 2019) 
    7.4 Level of Awareness 
    7.5 Fracture Registries 
    7.6 Government Policies 
    7.7 Guidelines 
    7.8 Reimbursement of Medication

8. Korea 
    8.1 Korea Osteoporosis Patients Population (2010 – 2019) 
    8.2 Korea Hip Fracture Patients Population (2010 – 2019) 
    8.3 Korea Osteoporosis Market (2010 – 2019) 
    8.4 Level of Awareness 
    8.5 Fracture Registries 
    8.6 Government Policies 
    8.7 Guidelines 
    8.8 Reimbursement of Medication

9. Brazil 
    9.1 Brazil Osteoporosis Patients Population (2010 – 2019) 
    9.2 Brazil Hip Fracture Patients Population (2010 – 2019) 
    9.3 Brazil Osteoporosis Market (2010 – 2019) 
    9.4 Level of Awareness 
    9.5 Guidelines & Policy 
    9.6 Reimbursement Policy

10. Russia 
    10.1 Russia Osteoporosis Patients Population (2010 – 2019) 
    10.2 Russia Hip Fracture Patients Population (2010 – 2019) 
    10.3 Russia Osteoporosis Market (2010 – 2019) 
    10.4 Level of Awareness 
    10.5 Government Policy 
    10.6 Guidelines 
    10.7 Reimbursement

11. United Kingdom 
    11.1 United Kingdom Osteoporosis Patients Population (2010 – 2019) 
    11.2 United Kingdom Hip Fracture Patients Population (2010 – 2019) 
    11.3 United Kingdom Osteoporosis Market (2010 – 2019) 
    11.4 Guidelines 
    11.5 Reimbursement Policy

12. France 
    12.1 France Osteoporosis Patients Population (2010 – 2019) 
    12.2 France Hip Fracture Patients Population (2010 – 2019) 
    12.3 France Osteoporosis Market (2010 – 2019) 
    12.4 Guidelines 
    12.5 Reimbursement Policy

13. Germany 
    13.1 Germany Osteoporosis Patients Population (2010 – 2019) 
    13.2 Germany Hip Fracture Patients Population (2010 – 2019) 
    13.3 Germany Osteoporosis Market (2010 – 2019) 
    13.4 Guidelines 
    13.5 Reimbursement Policy

14. United States 
    14.1 United States Osteoporosis Patients Population (2010 – 2019) 
    14.2 United States Hip Fracture Patients Population (2010 – 2019) 
    14.3 United States Osteoporosis Market (2010 – 2019) 
    14.4 Policy 
    14.5 Guidelines 
    14.6 Reimbursement Policy

15. Growth Driver 
    15.1 Widespread Vitamin D Deficiency & Low Calcium Intake 
    15.2 Globally Increasing Ageing Population & Life Expectancy

16. Challenges 
    16.1 Lack of Reimbursement / Other Restrictions for Reimbursement 
    16.2 Limited Access of Diagnostic Tools & Low Levels of Public and Health Professional Awareness 
    16.3 Lack of Government Osteoporosis Policy, Guidelines & National Health Priority in Asia Pacific Countries

17. Key Players Osteoporosis Drugs Sales & Forecast 
    17.1 Merck Osteoporosis Drugs Sales (2010 – 2019) 
    17.2 Sanofi Osteoporosis Drugs Sales (2010 – 2019) 
    17.3 Novartis Osteoporosis Drugs Sales (2010 – 2019) 
    17.4 Eli Lilly Osteoporosis Drugs Sales (2010 – 2019) 
    17.5 Amgen Osteoporosis Drugs Sales (2010 – 2019)

Get this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=529617

Contact US:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)           

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.